Cullinan Therapeutics Inc
(CGEM)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -79,368 | -37,340 | -155,101 | -129,538 | -90,355 |
| Depreciation Amortization | 153 | 76 | 310 | 233 | 153 |
| Accounts payable and accrued liabilities | -938 | 1,214 | -167 | -1,709 | -169 |
| Other Working Capital | -7,052 | -5,904 | -339 | -3,649 | -3,468 |
| Other Operating Activity | 12,667 | 3,707 | 21,022 | 18,519 | 11,836 |
| Operating Cash Flow | $-74,538 | $-38,247 | $-134,275 | $-116,144 | $-82,003 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -208 | -208 | -208 |
| Purchase Of Investment | -456,298 | -131,369 | -373,383 | -307,371 | -170,592 |
| Sale Of Investment | 284,142 | 144,325 | 409,397 | 291,915 | 198,094 |
| Investing Cash Flow | $-172,156 | $12,956 | $35,806 | $-15,664 | $27,294 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 1,825 | 1,825 | 1,825 |
| Common Stock Issued | 267,073 | 1,085 | 38,926 | 38,678 | 38,566 |
| Other Financing Activity | -3,792 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $263,281 | $1,085 | $40,751 | $40,503 | $40,391 |
| Beginning Cash Position | 98,434 | 98,434 | 156,152 | 156,152 | 156,152 |
| End Cash Position | 115,021 | 74,228 | 98,434 | 64,847 | 141,834 |
| Net Cash Flow | $16,587 | $-24,206 | $-57,718 | $-91,305 | $-14,318 |
| Free Cash Flow | |||||
| Operating Cash Flow | -74,538 | -38,247 | -134,275 | -116,144 | -82,003 |
| Capital Expenditure | N/A | N/A | -208 | -208 | -208 |
| Free Cash Flow | -74,538 | -38,247 | -134,483 | -116,352 | -82,211 |